Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT ID: NCT00005823
Last Updated: 2013-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
2000 participants
INTERVENTIONAL
1998-12-31
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This randomized phase III trial is studying intensive regimens of chemotherapy to see how well they work compared to nonintensive regimens of chemotherapy in treating older patients with acute myeloid leukemia or myelodysplastic syndrome.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Compare the response rate, survival, quality of life, and supportive care requirements with intensive versus nonintensive chemotherapy in older patients with acute myeloid leukemia or high risk myelodysplastic syndrome.
* Compare response achievement, response duration, survival, toxicity and supportive care requirements with differing doses of daunorubicin and cytarabine in these patients receiving intensive chemotherapy.
* Determine the efficacy of PSC 833 in enhancing the effects of daunorubicin in these patients receiving intensive chemotherapy.
* Compare relapse rate, deaths in complete remission, disease free survival, and survival with short versus long intensive chemotherapy in these patients.
* Compare response achievement, response duration, survival, toxicity, quality of life, and resource use with hydroxyurea versus cytarabine in these patients receiving low dose chemotherapy.
* Determine response achievement, response duration, survival, toxicity, quality of life, and supportive care requirements with the addition of tretinoin to the nonintensive chemotherapy in these patients.
* Assess the correlation between P-gp and BCL-2 in family members and treatment outcomes and other prognostic factors in these patients with these treatment regimens.
OUTLINE: This is a randomized, multicenter study. Patients are randomized or electively assigned to either intensive or nonintensive chemotherapy\*.
Intensive chemotherapy
* Induction therapy: Patients are randomized to 1 of 6 treatment arms. Patients receive 2 courses of chemotherapy comprising 1 of 2 daunorubicin doses, 1 of 2 cytarabine doses, thioguanine, and with or without PSC 833.
Patients receive daunorubicin IV once daily on days 1-3 with cytarabine IV twice daily and oral thioguanine once daily on days 1-10 during course 1. Treatment repeats in approximately 31 days as in course 1 except cytarabine and thioguanine are given only on days 1-8.
* Arm I: Patients receive higher dose of daunorubicin, lower dose of cytarabine, and thioguanine.
* Arm II: Patients receive higher dose of daunorubicin, higher dose of cytarabine, and thioguanine.
* Arm III: Patients receive lower dose of daunorubicin, lower dose of cytarabine, and thioguanine.
* Arm IV: Patients receive lower dose of daunorubicin, higher dose of cytarabine, and thioguanine.
* Arm V: Patients receive treatment as in arm III in combination with continuous infusion of PSC 833 beginning day 1.
* Arm VI: Patients receive treatment as in arm IV in combination with continuous infusion of PSC 833 beginning on day 1.
Patients with refractory disease after the first course of induction chemotherapy may continue with the intensive protocol arm or enter the nonintensive arm\*. Patients who do not achieve complete remission after completion of induction chemotherapy are removed from study. Patients in complete remission after induction therapy receive consolidation therapy.
* Consolidation therapy: Patients in complete remission after induction are randomized to either short or long consolidation.
* Short consolidation: Patients receive mitoxantrone IV on days 1-3 and cytarabine IV over 2 hours twice daily on days 1-3.
* Long consolidation: Patients complete short consolidation and then receive idarubicin IV over 5 minutes once daily on days 1 and 3, cytarabine IV over 2 hours twice daily and etoposide IV over 1 hour once daily on days 1-3.
Non-intensive chemotherapy\*
* Patients are randomized to 1 of 4 treatment arms.
* Arm I: Patients receive oral hydroxyurea as necessary to control WBC count until treatment failure.
* Arm II: Patients receive hydroxyurea as in arm I and oral tretinoin daily for up to 16 weeks.
* Arm III: Patients receive low dose cytarabine subcutaneously twice daily on days 1-10 every 28 days for a minimum of 4 courses.
* Arm IV: Patients receive cytarabine as in arm III plus oral tretinoin daily for up to 16 weeks.
NOTE: \*Patients with liver function test \> 2 times upper limit of normal are not eligible for nonintensive randomization
Quality of life is assessed at study entry, and then at 1, 3, and 6 months.
Patients are followed at one year.
PROJECTED ACCRUAL: Approximately 2,000 patients (1,200 to intensive arm and 800 to nonintensive arm) will be accrued for this study over 5 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
cytarabine
daunorubicin hydrochloride
etoposide
hydroxyurea
idarubicin
mitoxantrone hydrochloride
thioguanine
tretinoin
valspodar
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Acute myeloid leukemia (de novo or secondary) OR
* Myelodysplastic syndrome
* More than 10% myeloblasts in the bone marrow
* Refractory anemia with excess blasts
* Refractory anemia with excess blasts in transformation
* Chronic myelomonocytic leukemia
* No acute promyelocytic leukemia (FAB type M3)
* No blastic phase chronic myeloid leukemia
PATIENT CHARACTERISTICS:
Age:
* 60 and over (younger patients allowed if intensive chemotherapy not indicated)
Performance status:
* Not specified
Life expectancy:
* Not specified
Hematopoietic:
* Not specified
Hepatic:
* No liver function test ≥ 2 times normal (for non-intensive therapy arm)
Renal:
* Not specified
Cardiovascular:
* No myocardial infarction within past 6 months in patients receiving daunorubicin or PSC 833
Other:
* No other concurrent active malignancy
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Not specified
Chemotherapy:
* No prior cytotoxic chemotherapy for leukemia
Endocrine therapy:
* Not specified
Radiotherapy:
* Not specified
Surgery:
* Not specified
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Leukemia Research Fund
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alan K. Burnett, MD, FRCP
Role: STUDY_CHAIR
University Hospital of Wales
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Queen Elizabeth Hospital at University of Birmingham
Birmingham, England, United Kingdom
University College Hospital
London, England, United Kingdom
University Hospital of Wales
Cardiff, Wales, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Seedhouse CH, Grundy M, White P, Li Y, Fisher J, Yakunina D, Moorman AV, Hoy T, Russell N, Burnett A, Pallis M; National Cancer Research Network. Sequential influences of leukemia-specific and genetic factors on p-glycoprotein expression in blasts from 817 patients entered into the National Cancer Research Network acute myeloid leukemia 14 and 15 trials. Clin Cancer Res. 2007 Dec 1;13(23):7059-66. doi: 10.1158/1078-0432.CCR-07-1484.
Burnett AK, Milligan D, Hills RK, et al.: Does all-transretinoic acid (ATRA) have a role in non-APL acute myeloid leukaemia? Results from 1666 patients in three MRC trials. [Abstract] Blood 104 (11): A-1794, 2004.
Burnett AK, Milligan D, Goldstone A, Prentice A, McMullin MF, Dennis M, Sellwood E, Pallis M, Russell N, Hills RK, Wheatley K; United Kingdom National Cancer Research Institute Haematological Oncology Study Group. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol. 2009 May;145(3):318-32. doi: 10.1111/j.1365-2141.2009.07604.x. Epub 2009 Mar 8.
Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, Wheatley K. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007 Mar 15;109(6):1114-24. doi: 10.1002/cncr.22496.
Burnett AK, Milligan DW, Prentice AG, et al.: Modification or dose or treatment duration has no impact on outcome of AML in older patients: preliminary results of the UK NCRI AML14 trial. [Abstract] Blood 106 (11): A-543, 2005.
Burnett AK, Milligan D, Prentice AG, et al.: Low dose Ara-C versus hydroxyurea with or without retinoid in older patients not considered fit for intensive chemotherapy: the UK NCRI AML14 trial. [Abstract] Blood 104 (11): A-872, 2004.
Pallis M, Truran L, Grundy M, et al.: P-Glycoprotein overexpresion and internal tandem duplications of FLT3 are characteristic of discrete populations of elderly AML patients. [Abstract] Blood 104 (11): A-196, 2004.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LRF-AML14
Identifier Type: -
Identifier Source: secondary_id
EU-20016
Identifier Type: -
Identifier Source: secondary_id
ISRCTN62207270
Identifier Type: -
Identifier Source: secondary_id
CDR0000067831
Identifier Type: -
Identifier Source: org_study_id